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ABSTRACT 
Background: For patients at high risk for bleeding, a polymer-free metallic stent coated with 
biolimus-A9 followed by one-month dual antiplatelet therapy was safer and more effective than 
a bare metal stent at one year.  
Objectives: Longer-term follow-up is needed to determine whether these benefits are 
maintained. 
Methods: In a prospective, multi-center, double blind trial, we randomly assigned 2466 high 
bleeding risk patients to receive a drug coated stent (DCS) or a bare metal stent (BMS) followed 
by one month dual antiplatelet therapy and 98.1% completed a two-year follow-up. The primary 
safety end point was a composite of cardiac death, myocardial infarction (MI), or stent 
thrombosis (ST). The primary efficacy end point was clinically driven target-lesion 
revascularization.   
Results: At 2 years, the primary safety endpoint had occurred in 147 DCS (12.6%) and 180 
BMS patients (15.3%) (hazard ratio 0.80; 95% CI, 0.64 to 0.99; p=0.039). Clinically driven 
target-lesion revascularization occurred for 77 DCS (6.8%) and 136 BMS patients (12.0%) 
(hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P<0.0001). Major bleeding occurred in 8.9% DCS and 
9.2% BMS patients (p=0.95), and a coronary thrombotic event (MI and/or ST) in 8.2% DCS and 
10.6% BMS patients (p=0.045). Mortality was 27.1% one year after a major bleed, and 26.3% 
one year after a thrombotic event. At two years, multivariate correlates of major bleeding were 
age > 75, anemia, raised plasma creatinine and planned long-term anticoagulation. Correlates of 
the primary safety endpoint were age anemia, congestive heart failure, multivessel disease, 
number of stents implanted and use of a BMS rather than a DCS. 
Conclusions: The safety and efficacy benefits of DCS over BMS were maintained up to two 
years in high bleeding risk patients.  During that period, overall rates of major bleeding and 
coronary thrombotic events were no different and associated with a substantial and comparable 
mortality risk.  
 
Clinical Trial: NCT01623180. 
 
Keywords: drug-coated stent, DAPT, bleeding, thrombosis, bare-metal stent 
 
Abbreviations: 
BARC =  Bleeding Academic Research Consortium 
BMS =  Bare metal stents 
DAPT =  Dual antiplatelet therapy 
DCS =  Drug-coated stents 
DES =  Drug-eluting stents 
HBR =  High bleeding risk 
PCI =   Percutaneous coronary intervention 
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Introduction 
Patients at high bleeding risk (HBR) who require percutaneous coronary intervention 
(PCI) are a challenging group who need careful evaluation of both their thrombotic and bleeding 
risks when selecting a stent and deciding on duration and intensity of antithrombotic 
management (1,2). Little evidence exists to aid such decisions, since HBR patients are mostly 
excluded from clinical trials of antithrombotics and PCI (3-6). Until recently, the perceived need 
for a very short course of dual antiplatelet treatment (DAPT) often led operators to prefer a bare 
metal stent (BMS) to a drug eluting stent (DES) for such patients (7,8). 
The Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug-Coated 
Stent versus the Gazelle Bare-Metal Stent in Patients at High Bleeding Risk (LEADERS FREE) 
trial recently showed that, together with a one month DAPT course, a polymer-free metallic drug 
coated stent (DCS) was both safer and more effective than a BMS for patients at high risk of 
bleeding followed for one year (1). This DCS (BioFreedom, Biosensors Interventional 
Technologies Pte, Ltd., Singapore) transfers biolimus A9, a highly lipophilic sirolimus analog, 
into the vessel wall over a one month period (9). This is in contrast to currently available 
polymer-coated Drug-Eluting Stents (DES), which generally release drug over a period of 
several months. 
Limited encouraging five-year data are available from the first-in-man evaluation of this 
DCS for 60 selected patients treated with 6-12 months DAPT (10). For HBR patients with one-
month DAPT treatment, further evidence is needed to assess whether the first year benefits of 
DCS over BMS are maintained in the long term. Also, because of the unique features of the 
LEADERS FREE design (unusual patient population, very short DAPT) together with the 
observed high rate of major bleeding in both arms after one year,1 it appeared important to 
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evaluate the balance of the two-year risks and the baseline and procedure correlates of the 
primary safety endpoint and of major bleeding events.  
Methods 
Patients 
Patient selection and study design of the LEADERS FREE trial have been described 
previously (1,11). Inclusion required a clinical indication for PCI together with one or more HBR 
criteria: most frequently age 75 or above, planned prolonged oral anticoagulation, renal 
insufficiency, planned major surgery, anemia or recent transfusion and cancer. Such patients 
were potential candidates for a BMS instead of a DES, owing to their perceived need for only 
one month DAPT. 
Study Device and Procedure 
The BioFreedom polymer-free biolimus A9 coated stent, the control Gazelle bare-metal 
stent (Biosensors Europe and Biosensors Interventional Technologies) and the PCI procedure 
have been described previously (1,11). Importantly, a double-blind design was used. All patients 
were to receive DAPT including both aspirin (75 to 250 mg once daily) and a P2Y12 inhibitor 
(with clopidogrel preferred) for 30 days followed by a single antiplatelet agent thereafter (aspirin 
preferred). Patients requiring a vitamin K antagonist could be treated either by triple therapy or a 
vitamin K antagonist plus clopidogrel only during the first 30 days. Patients had follow-up visits 
at 30 and 365 days, and were contacted either on site or by telephone at 60, 120 and 730 days. 
Ischemia testing and angiographic evaluation during follow-up was left to the investigator’s 
discretion. 
Study Design and Oversight 
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A total of 2466 patients from 68 sites were randomized to receive either the BioFreedom 
DCS or the Gazelle BMS. The study was sponsored by Biosensors Europe (Morges, 
Switzerland), and conducted by the Cardiovascular European Research Center (CERC; Massy, 
France), an independent research organization paid by the sponsor.  The respective roles of the 
Executive Committee, the Sponsor, CERC and authors have remained unchanged (1). The first 
author, statisticians (JG, SC) and Executive Committee had unrestricted access to the data and 
prepared all drafts of the manuscript; they attest to the completeness and accuracy of all data and 
to the adherence to study protocol. The Ethics Committee at each site approved the trial, and 
written informed consent was obtained from all patients. 
Study End Points 
The primary safety endpoint was the cumulative incidence of a composite of cardiac 
death, myocardial infarction, or definite or probable stent thrombosis. The primary efficacy 
endpoint was the incidence of clinically driven target-lesion revascularization. Pre-specified 
secondary end points included all-cause and cardiac mortality, bleeding (Bleeding Academic 
Research Consortium (BARC) definitions) (12), myocardial infarction (3rd Universal definition) 
(13), stent thrombosis (Academic Research Consortium (ARC) definitions) (14), and types of 
coronary revascularization.  A clinical events committee adjudicated all components of the 
primary end points and all bleeding events, according to pre-defined criteria (1,11). 
Statistical Analysis 
All results are based on a modified intention to treat analysis after exclusion of 34 
patients who had no suitable lesion for PCI (1). Continuous variables are presented as means, 
categorical data as counts and percentages. Time-to-event analyses were performed using 
Kaplan–Meier plots, log-rank tests and proportional-hazard models to estimate hazard ratios and 
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their 95% confidence intervals. Proportional hazard assumptions were checked using Schoenfeld 
residuals. Patients were censored at death, withdrawal from study, scheduled end of study, or 730 
days post-randomization, whichever occurred first. We performed sensitivity analyses using the 
Fine and Gray method to estimate cumulative incidence of events whilst adjusting for the 
competing risk of mortality (15). 
For major bleeding we used the BARC 3, 4 or 5 bleeding definition. To explore 
covariates associated with major bleeding and the primary safety endpoint, we performed 
multivariate analyses investigating the potential influence of 32 baseline and procedural 
variables (Online Table 1) by means of proportional hazard models. We selected a final model 
for each outcome by using forward stepwise variable selection on data with complete 
information on all covariates and an inclusion criterion of p<0.01. Based on the trial results, we 
forced inclusion of BMS stent in the model for the primary safety endpoint. We used multiple 
imputations with chained equations to impute missing data on covariates when calculating 
hazard ratios. We used 10 imputed datasets and combined estimates and standard errors across 
studies using Rubin’s rules (16). To calculate the hazard ratios for death following a thrombotic 
or major bleeding event, follow-up of each patient was divided into time spent before and after a 
major bleeding or thrombotic event. The association between these events and subsequent 
mortality was entered into a Cox-proportional hazards model as a time-updated categorical 
variable that enters the model on the day of the event (Online Appendix E). HRs therefore 
compare the hazard of death after an event to the hazard before an event (which includes the 
hazard in patients who do not have an event during follow up). We further broke each patient’s 
follow-up after a thrombotic or major bleeding event into three time intervals (0-7, 8-30, and 31-
365 days), based upon similar analyses performed in other studies (17). 
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Hazard ratios for death were adjusted for correlates of thrombotic or major bleeding 
events. Analyses were performed with Stata Software, version 14.1 (StataCorp) and SAS 9.3 and 
all p-values were calculated using 2-sided hypothesis tests. 
Results 
Patients 
Of the 2432 patients who underwent PCI, 2386 (98.1%) were followed until death or 730 
days (Online Figure 2). Only 9 patients in the DCS arm and 3 in the BMS arm were lost to 
follow-up before 2 years. Patients were included based on pre-defined criteria of an increased 
bleeding risk, mainly age ≥75 (64.3%), prolonged oral anticoagulation (36.1%), renal failure 
(19.1%), planned major surgery (16.4%), hemoglobin <11g/l or recent transfusion (15.6%) and 
cancer in the previous 3 years (9.8%). The DCS and BMS groups were well matched with regard 
to baseline characteristics (Online Table 3). 
At 730 days, 78.8% of patients in the DCS group and 76.8% in the BMS group were 
receiving single antiplatelet therapy, 5.3% and 7.6% respectively had dual antiplatelet therapy, 
15.8% and 15.6% respectively were taking no antiplatelet drug and 37.7% and 38.0% 
respectively were taking oral anticoagulants.  Details regarding antithrombotic treatment are 
given in Online Table 4. 
Primary Outcomes at 2 Years 
We previously reported outcomes using a 390 day time-point (1). In order to facilitate 
comparisons between the first and second follow-up year, time-points of 365 and 730 days were 
used for 1 and 2 years in the present analysis. Between 1 and 2 years, there were 53 new 
occurrences of a primary safety endpoint in 37 DCS patients and 44 in 29 BMS patients. The 
primary safety outcomes at 2 years occurred more frequently in the BMS than in the DCS group 
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(15.3% vs.12.6%, hazard ratio, 0.80; 95% confidence interval [CI], 0.64 to 0.99, P=0.039) 
(Table 1, Figure 1 and Central Illustration). 
Between 1 and 2 years, there were 24 new clinically driven target-lesion 
revascularizations (primary efficacy end point) in 20 patients of the DCS group and 43 in 29 
patients of the BMS group. Clinically driven target-lesion revascularization was required at least 
once in 6.8% of DCS and 12.0% of BMS patients at 2 years (hazard ratio, 0.54; 95% CI, 0.41 to 
0.72, P<0.0001) (Table 1, Figure 1 and Central Illustration). 
Other Clinical Outcomes 
Other clinical outcomes are summarized in Table 1. There were no significant 
differences in mortality between the DCS and BMS groups in either all-cause (13.1% vs. 13.8%, 
hazard ratio 0.94; 95% CI, 0.75 to 1.17, P=0.57) or cardiac mortality (6.6% vs. 6.9%, hazard 
ratio 0.94; 95% CI, 0.69 to 1.28, P=0.69) (Table 1). Between 1 and 2 years follow-up, 48 
myocardial infarctions occurred (25 in 20 patients of the DCS group, and 23 in 14 patients of the 
BMS group) and two very late definite or probable stent thromboses (1 in the DCS group and 1 
in the BMS group). 
The incidence of coronary thrombotic events from randomization to 2 years (defined as 
any myocardial infarction and/or definite or probable stent thrombosis) was significantly lower 
with DCS than with BMS (8.2% vs. 10.6%, p=0.045) (Table 1). Major bleeding over 2 years 
occurred at a similar rate in both DCS and BMS groups (8.9% vs. 9.2% p=0.95) (Central 
Illustration). Pre-specified subgroup comparisons for the primary efficacy and safety end points 
are shown in Online Figure 3. These analyses show a consistent treatment effect across most 
subgroups. However, interaction testing suggested heterogeneity of treatment effect with regard 
to the primary safety end point according to whether or not the patient presented with an acute 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
coronary syndrome, and with regard to the primary efficacy end point in patients with a 
CRUSADE score greater than 35. Both these subgroups had already been identified at the one-
year follow-up. (1). 
We identified eight baseline and procedural characteristics correlated with major bleeding 
and primary safety endpoint events at two years: four were related to the safety endpoint only 
(congestive heart failure, multivessel disease, number of stents and stent type), two to bleeding 
events only (planned oral anticoagulation and raised plasma creatinine) and two to both (age >75 
and low hemoglobin) (Table 2). Of note, use of a BMS had a 33% relative increase in the hazard 
for safety endpoint events (p=0.04) compared to DCS after covariate adjustment. 
The risks of all-cause death one year after a major bleed and one year after a coronary 
thrombotic event were 27.1% and 26.3% respectively (Figure 2A). Both show a similar pattern 
with very marked excess mortality risk within the first week after such events, especially for 
coronary thrombotic events, which then attenuates over time (Figure 2B). A major bleed 
remains associated with a significant excess mortality risk during 31-365 days after the event 
(adjusted hazard ratio 2.54, p<0.001). These mortality patterns were no different for both DCS 
and BMS groups, though the former has a reduced risk of a coronary thrombotic event (Table 1). 
Discussion 
For HBR patients receiving a one-month course of DAPT, two-year follow up in the 
LEADERS FREE trial demonstrates, for both efficacy and safety, the sustained superiority of the 
BioFreedom polymer free biolimus A9-coated stent (DCS) compared to a similar bare-metal 
stent (BMS). In this patient population, both the risks of major bleeding and of a composite of 
cardiac death, myocardial infarction or stent thrombosis were high.  Both type of events were 
associated with several baseline and procedure characteristics, and when two of the components 
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of the primary safety endpoint (MI and/or ST) were analyzed for their associated post-event one 
year all-cause mortality, this was high: 26.3% and comparable to that observed after major 
bleeding (27.1%).  
Encouragingly for the DCS, no “catch-up” of target lesion revascularization was 
observed beyond one year. This is in keeping with studies of a polymer-free stent as well as a 
rapid-elution permanent polymer DES (18,19) and different from what has been seen with first 
generation DES (20). It is plausible that biolimus A9 is particularly well suited to rapid delivery 
into the vessel wall because of its marked lipophilicity (9). The low incidence of very late stent 
thrombosis in both trial arms (<0.1%) suggests that absence of any polymer on the DCS may 
contribute to its long-term safety despite the very short DAPT, and compares favorably with 
stent thrombosis rates for polymer-coated DES, especially in this high risk population (21-26). 
These data confirm the good long-term results of DCS observed in a previous study (10). 
However, HBR patients continue to suffer a high incidence of adverse events beyond the first 
year, most likely due to advanced age, major co-morbidities, and possibly because of only partial 
revascularization in some patients (multivessel disease was reported in 62% of patients, but 
multivessel index revascularization was done in only 22%) (1). Two-year mortality was 13.1% 
for DCS vs. 13.8% for BMS patients. This is higher than observed in all-comer trials, and again 
points to the impact of comorbid conditions (23,26-29). 
The ZEUS trial randomized 1606 patients considered uncertain DES candidates to either 
a first generation rapid-elution zotarolimus DES with a biocompatible permanent polymer or a 
thin-strut BMS (30). Among these patients, 52% had a high bleeding risk, and their median 
DAPT duration was 30 days. The overall trial found better safety and efficacy for the DES, even 
more pronounced for HBR patients with substantial reductions in myocardial infarction and 
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target vessel revascularization and a stent thrombosis rate of 2.6% vs. 6.2% for DES and BMS 
respectively (2,30). Two other randomized trials evaluated this rapid-elution Zotarolimus-eluting 
DES in low bleeding risk patients, and concluded that a 3 month course of DAPT was as safe 
and effective as a prolonged course of DAPT, but both were somewhat underpowered (5,6). The 
larger DAPT trial enrolled 9961 low to medium bleeding risk patients after implantation of 
several slow-eluting DES and an uneventful first 12 months period, and evaluated prolonged 
DAPT. Rates of myocardial infarction and stent thrombosis were significantly lower with 30 
than with 12 months DAPT, but at the cost of an increase in bleeding (31). 
The recent NORSTENT trial randomized 9013 patients to either a contemporary DES or 
a thin-strut BMS, and found that with a 9 month DAPT course in both arms and after a 6 year 
follow-up, both stent types were equivalent for safety (cardiac death or MI), while DES were 
superior in terms of need for repeat revascularisation and a lower rate of stent thrombosis (32). 
Since both the DAPT duration and the patients risk profiles were very different from those of 
LEADERS FREE, we believe that both trials complement rather than contradict each other. 
BMS design is unlikely to be a major factor, since the thin strut BMS used in NORSTENT were 
very similar to those used in ZEUS, where active stents were also both safer and more effective 
than BMS in HBR patients treated with a short course of DAPT (2,30). 
Interest in shortening DAPT when needed is now considerable, and there are at least 9 
randomized trials currently planned or ongoing to evaluate DAPT regimens of 3 months or less 
after coronary stenting. Some use stents with rapid drug transfer to the vessel wall, a logical 
feature when very short DAPT appears desirable, while others use stents coated with either a 
permanent or biodegradable polymer that delivers the anti-proliferative drug over several 
months. Whether such strategies are safe remains to be demonstrated (33). 
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One important finding in our trial is that both bleeding and coronary thrombotic event 
rates (MI and/or ST) are high and similar in HBR patients. While this balance has already been 
described for all-comer patients (34), both types of events are clearly more frequent in HBR 
patients. In the present trial, 8.2% of patients suffered a coronary thrombotic event (MI and/or 
ST) and 8.9% % a major bleeding event at 2 years in the DCS group, while these events occurred 
in 10.6% for thrombotic and 9.2% for bleeding events in the BMS group. In the PARIS registry 
that analyzed 4190 patients after coronary stenting, the majority of whom were maintained on 
DAPT for at least a year, coronary thrombotic events occurred in 3.8% and major BARC 
bleeding (BARC 3 or 5) in 3.3%. (34,37). This difference is again most probably due to the more 
advanced age and greater co-morbidity of HBR patients, compared to an “all-comer” population. 
Of interest is the fact that the ratio of thrombotic to bleeding events at two years was very similar 
in both trials (0.92 for the DCS arm, 1.15 for the BMS arm in LEADERS FREE and 1.15 in 
PARIS). 
The risk of ensuing mortality is also high, especially soon after the event. Of note is the 
persistently high excess mortality out to one year after a major bleed. These findings are similar 
to those of ACUITY (17), a trial focused on patients presenting with acute coronary syndrome, 
but the adjusted hazard ratios for mortality associated with major bleeding and thrombotic events 
were markedly higher in LEADERS FREE, again suggesting that such events are of greater 
consequence for HBR than for younger patients with less comorbidity. The trade-off for any 
change in anti-thrombotic management may be finely balanced: a longer DAPT course might 
decrease thrombotic complications, but, most likely at the price of an increased risk of major 
bleeding (35,36). LEADERS FREE was designed to compare a new stent to a BMS using the 
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accepted standard of one month DAPT in HBR patients, but the optimal duration of DAPT still 
remains to be determined in this high-risk population. 
Among characteristics associated with either bleeding or the primary safety endpoint 
(Table 2), anemia, like age, was related to both. This stresses the limitations of using certain 
correlates to assess either bleeding or thrombotic risks in isolation when deciding about the 
intensity and duration of DAPT. As previously reported, anemia is a powerful prognostic 
indicator after PCI, more so for bleeding than for thrombosis in our series, and has historically 
received insufficient attention (38-40). For avoidance of bleeding, the need for long-term oral 
anticoagulation should always be carefully reassessed after PCI (40). Renal insufficiency was 
correlated only with bleeding in our series, while it has also been reported as a predictor of 
thrombotic complications by others (34,37). It could either be that its thrombotic risk is of 
comparative lesser importance for HBR patients who by definition often have other co-morbid 
conditions, or that patients with the most severe renal dysfunction are already captured by their 
associated anemia. 
Two study limitations should be acknowledged. First, results are not directly applicable 
to non-HBR patient who are likely to tolerate longer courses of DAPT. For non-HBR patients, a 
6-12 months course, perhaps longer, is associated with benefit (7,8,31) and a minimum of 12 
months remains the Guideline when such patients present with ACS (7,40).  Second, our results 
cannot be generalized to other DES or DCS with different drugs or slower elution kinetics. 
Further evidence is needed, and those trials are currently underway. 
In summary, the safety and efficacy benefits of a polymer-free biolimus A9-eluting stent 
vs. a bare metal stent together with a short one-month DAPT course were maintained during two 
years follow-up. The persistently high incidence of both bleeding and coronary thrombotic 
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events in HBR patients needs wider recognition, and deserves full attention in future trials of 
antithrombotic therapy.  
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Figure Legends 
Central Illustration. High Bleeding Risk Patients after Polymer-Free Drug-Coated Stents: 
Primary safety endpoint, primary efficacy endpoint, major bleeding, and individual 
components of the primary safety endpoint. The Kaplan-Meier time-to-event curves show the 
cumulative percentage of patients with the primary safety end point (a composite of cardiac 
death, myocardial infarction, or stent thrombosis) (Panel A), the primary efficacy end point 
(clinically driven target-lesion revascularization) (Panel B), major bleeding (Panel C), and the 
three components of the safety endpoint (PANELS D, E, and F). 
 
Figure 1: Landmark analysis at one year for the primary safety and primary efficacy 
endpoints. The Kaplan Meier time-to-event curves show the cumulative percentage of patients 
who reached the primary safety endpoint (left panel) and the primary efficacy endpoint (right 
panel) for the first time between 365 and 730 days. 
  
Figure 2. One-year mortality following a major bleed+ or a coronary thrombotic 
event.*Kaplan Meier time-to-event curves show the cumulative percentage of patients who died 
within one year following a major bleed or a thrombotic event* throughout the 2 year study 
period. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
Table 1. Clinical Outcomes at 1 Year and 2 Years with a Drug-Coated or Bare-Metal Stent 
 
Outcome  1 Year   2 Years  
 DCS 
(N=1221) 
BMS 
(N=1211) 
p DCS 
(N=1221) 
BMS 
(N=1211) 
p 
Primary safety end 
point: cardiac death, 
MI, or stent thrombosis 
110 (9.2) 151 (12.7) 0.006 147 (12.6) 180 (15.3) 0.039 
Primary efficacy end 
point: clinically driven 
TLR 
57 (4.9) 107 (9.3) <0.001 77 (6.8) 136 (12.0) <0.0001 
Death        
From any cause 91 (7.5) 105 (8.7) 0.27 156 (13.1) 164 (13.8) 0.57 
From cardiac causes 49 (4.1) 61 (5.1) 0.23 76 (6.6) 80 (6.9) 0.69 
MI‡ 
      
Any 70 (5.9) 103 (8.7) 0.008 90 (7.4) 117 (10.1) 0.04 
Q-wave infarction 6 (0.5) 7 (0.6) 0.77 6 (0.5) 10 (0.9) 0.31 
Non-Q-wave infarction 55 (4.7) 78 (6.7) 0.04 67 (5.8) 86 (7.4) 0.09 
Undetermined type 10 (0.8) 26 (2.2) 0.007 18 (1.6) 31 (2.7) 0.06 
Stent thrombosis‡ 
      
Definite or probable 24 (2.0) 26 (2.2) 0.75 25 (2.1) 27 (2.3) 0.76 
Definite 16 (1.3) 17 (1.4) 0.84 17 (1.4) 17 (1.4) 0.98 
Probable 8 (0.7) 9 (0.8) 0.80 8 (0.7) 10 (0.9) 0.63 
Possible 25 (2.2) 26 (2.2) 0.85 36 (3.2) 35 (3.1) 0.95 
Early definite or 
probable  
(acute + sub-acute) 
12 (1.0) 15 (1.2) 0.55 - - - 
Late definite or 
probable 
13 (1.1) 11 (1.0) 0.70 - - - 
Very late definite or 
probable 
- - - 1(0.1) 1 (0.1) 0.99 
Coronary thrombotic 
event*‡ 
76 (6.4) 109 (9.3) 0.01 96 (8.2) 123 (10.6) 0.045 
Bleeding‡§ 
      
BARC 1-5 213 (17.9) 225 (19.1) 0.50 258 (22.0) 255 (22.3) 0.89 
BARC 2-5 165 (13.9) 173 (14.8) 0.61 204(17.4) 206 (17.9) 0.83 
BARC 3-5 85 (7.2) 85 (7.3) 0.96 105 (8.9) 105 (9.2) 0.95 
Revascularization       
Any TVR 65 (5.6) 119 (10.3) <0.001 91 (8.1) 151 (13.3) <0.0001 
TVR by CABG 4 (0.3) 11 (1.0) 0.07 6 (0.5) 12 (1.1) 0.14 
Any revascularization 94 (8.1) 134 (11.6) 0.003 129 (11.4) 180 (15.9) 0.001 
Percentages are Kaplan–Meier estimates at 365 (1 year) and 730 days (2 years).  
* Any myocardial infarction and/or definite or probable stent thrombosis 
‡ Subcategories of myocardial infarction, stent thrombosis, or bleeding are not mutually exclusive, because patients 
could have more than one subtype of these events during follow-up. 
§Bleeding was defined according to the Bleeding Academic Research Consortium (BARC) definitions. BARC type 
0 indicates no bleeding, and BARC type 5 indicates fatal bleeding.11 
BMS: bare metal stent; CABG: coronary artery bypass grafting; DCS: drug coated stent; MI: myocardial infarction; 
TLR: target-lesion revascularization; TVR: target-vessel revascularization  
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Table 2: Multivariate correlates of primary safety endpoint*and major bleeding+ 
 
Hazard ratio  P 
Primary safety endpoint 
 
 
   
Age >75 years 1.56 (1.23 to 1.97) <0.001 
Hemoglobin (per 1 mmol/l < 9) 1.32 (1.19 to 1.46) <0.001 
Congestive heart failure at baseline 1.61 (1.23 to 2.11) 0.001 
Multivessel disease at baseline** 1.66 (1.27 to 2.18) <0.001 
Number of stents implanted (per additional stent) 1.13 (1.04 to 1.23) 0.005 
Bare metal stent 1.28 (1.03 to 1.59) 0.027 
   
Major bleeding event 
 
 
Age >75 years 1.52 (1.13 to 2.06) 0.006 
Hemoglobin (per 1 mmol/l < 9) 1.73 (1.52 to 1.96) <0.001 
Serum creatinine >150 umol/l 1.58 (1.10 to 2.27) 0.012 
Planned OAC use post-PCI 2.01 (1.51 to 2.68) <0.001 
 
* Primary safety endpoint: composite of cardiac death, myocardial infarction and 
definite/probable stent thrombosis  
+
 BARC 3-5 (Bleeding Academic Research Consortium) bleeding 
** Multivessel vessel disease includes patients with site-reported two or three vessel and/or left 
main disease.  
OAC: Oral anticoagulants; PCI: percutaneous coronary intervention 
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Table 3: 1-year mortality following a major bleed or coronary thrombotic event 
 Patients with 
event 
Deaths Person-
time at 
risk 
(years) 
Rate (per 
person-year 
at risk) 
Adjusted hazard ratio vs 
no event (95% CI) 
First year after event      
Thrombotic event      
No event or before event 2432 256 4137.3 0.06 1.00 (reference) 
0-365 days  219 64 257.3 0.25 4.43 (3.24 to 6.04) 
Major bleeding      
No event or before event 2432 255 4153.5 0.06 1.00 (reference) 
0-365 days  210 65 241.1 0.27 3.43 (2.49 to 4.74) 
      
Time since event      
Thrombotic event      
No event or before event 2432 256 4137.3 0.06 1.00 (reference) 
0-7 days  219 24 3.9 6.22 77.96 (49.29 to 123.30) 
8-30 days  195 11 11.8 0.93 11.51 (6.19 to 21.40) 
31-365 days 183 29 241.6 0.12 1.53 (0.93 to 2.53) 
Major bleeding      
No event or before event 2432 255 4153.5 0.06 1.00 (reference) 
0-7 days  210 16 3.8 4.2 36.11 (20.82 to 62.64) 
8-30 days  192 3 11.9 0.25 2.41 (0.76 to 7.65) 
31-365 days 186 46 225.4 0.2 2.36 (1.60 to 3.48) 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1 
SUPPLEMENTARY APPENDIX 
 
 
 
Table of contents 
A: LEADERS FREE Study organization      page 2 
B: Enrollment inclusion and exclusion criteria       page 8 
C. Study devices           page 10 
D: Endpoint definitions         page 11 
E: Methods for time-updated Cox proportional hazards models    page 18 
E: Supplementary Figures and Tables       page 19 
 Table S1: Covariates associated with major bleeding and primary safety  
 endpoint events included in the proportional hazard model    page 19 
 Figure S2: Study group assignment and follow-up     page 20 
 Table S3: Baseline Patient characteristics and inclusion criteria   page 21 
 Table S4: Antithrombotic medication during follow-up    page 23 
 Table S5: Subgroup analyses for primary safety and primary efficacy endpoints page 24 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2 
A: Study organization  
 
Leaders Free Executive Committee Members: 
Philip Urban (Hôpital de la Tour, Geneva, Switzerland), Marie-Claude Morice (ICPS, Générale de 
Santé, Massy, France), Alexander Abizaid (Instituto Dante Pazzanese de Cardiologia, São Paulo, 
Brazil), Ian T Meredith (Monash Heart, MCRC Monash University, Melbourne, Australia), Stuart J. 
Pocock (London School of Hygiene and Tropical Medicine, London, UK), Didier Carrié (Toulouse 
Rangueil Hospital, Toulouse, France), Christoph Naber (Elisabeth Krankenhaus, Essen, Germany), 
Samantha Greene (Biosensors Europe, Morges, Switzerland), Hans-Peter Stoll (Biosensors Europe, 
Morges, Switzerland) 
 
 
Steering Committee Members and Regional Coordinating Investigators: 
Luc Bilodeau (Royal Victoria Hospital, Montreal, Canada), Mariano Valdes-Chavarri (Arrixaca 
University Hospital, Murcia, Spain), Alaide Chieffo (San Raffaele Hospital, Milan, Italy), Haim 
Danenberg (Hadassah Hebrew University Medical Center, Jerusalem, Israel), Franz Eberli (Triemli 
Hospital, Zürich, Switzerland), Marcel Gosselink (Isala Klinieken, Zwölle, The Netherlands), Keith 
Oldroyd (West of Scotland Regional Heart & Lung Centre Golden Jubilee National Hospital, Glasgow, 
Scotland), Robayaah Zambahari (Institute Jantung Negara, Kuala Lumpur, Malaysia)  
 
 
Clinical Events Committee: 
Chairman: Roxana Mehran (Icahn School of Medicine at Mount Sinai, New York, New York, USA), 
Andreas Baumbach (Bristol Royal Infirmary, Bristol, UK), Stéphane Cook (University & Hospital 
Fribourg, Fribourg, Switzerland), Petr Kala (University Hospital Brno and Masaryk University, 
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Brno,Czech Republic), Jacques Machecourt (CHU A. Michallon, Grenoble, France), Josefina Mauri 
(Hospital Universiari Germans Trials I Pujol, Barcelona,Spain), Goran Olivecrona (Skane University 
Hospital, Lund Sweden), Sonia Petronio (Ospedale di Cisanello, Pisa, Italy), Flavio Ribichini 
(University of Verona, Verona, Italy), Leif Thuesen (Aalborg University Hospital, Aalborg, Denmark) 
 
Data Safety Monitoring Board:  
Chairman: Bernhard Meier (Bern University Hospital, Bern, Switzerland), Jean-Pierre Bassand 
(Emeritus, University Hospital Jean Minjoz, Besançon, France), Thomas Cuisset (Hôpital La Timone, 
Marseille, France), Eric Vicaut (Hôpital Fernand Widal, Paris, France)  
 
Data Coordination: 
Data Management: Cardiovascular European Research Center (CERC), Massy, France 
IWR/IVRS/e-CRF:  MERGE 
 
Statisticians: 
John Gregson (London School of Hygiene and Tropical Medicine, London, UK) 
Duolao Wang (London School of Hygiene and Tropical Medicine, London, UK) 
Samuel Copt (Biosensors Europe, Morges, Switzerland),  Romain Piault (Biosensors Europe, Morges, 
Switzerland), Karen Kapur (Biosensors Europe, Morges, Switzerland). The three statisticians employed 
by the sponsor (SC, RP and KK) helped develop and validate the programs for the analysis but were 
then not involved in any of the analysis, 
 
List of Investigators by Country: 
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France: Janusz Lipiecki (Pôle Santé République, Clermont-Ferraud, France). Philippe Brunel (Clinique 
de la Fontaine, Dijon, France), Philippe Garot (Hôpital Claude Galien ICPS, Générale de Santé, Quincy-
Sous-Sénart, France), Jacques Berland (Clinique Saint Hilaire, Rouen, France), Mohamed Abdellaoui 
(Groupe Hospitalier Mutualiste de Grenoble (GHM), Grenoble, France), Didier Carrié, CHU Toulouse 
Rangueil, Toulouse), Thomas Hovasse (Hôpital Privé Jacques Cartier, Massy), Luc Maillard, (GCS ES 
Axium – Rambot, Aix en Provence), Christian Spaulding (European Hospital Georges Pompidou, 
Paris), Marc Bedossa (CHU Rennes, Rennes), Jean Fajadet (Clinique Pasteur, Toulouse),  Eric Maupas 
(Clinique Les Franciscaines, Nîmes), Marc Eric Moulichon (Clinique Saint-Pierre, Perpignan), Eric Van 
Belle (Hôpital Cardiologique – CHRU de Lille, Lille) 
 
United Kingdom: Suneel Talwar (Dorset Heart Centre Royal Bournemouth Hospital, Bournemouth, 
UK), Ian B. A. Menown (Craigavon Cardiac Centre, Belfast), Keith Oldroyd (West of Scotland 
Regional Heart & Lung Centre Golden Jubilee National Hospital, Glasgow), Jonathan Byrne (Kings 
College Hospital, London), Simon Redwood (St Thomas’Hospital, London), Azfar Zaman (Freeman 
Hospital, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle), David Hildick-Smith (Sussex 
Cardiac Centre - Brighton and Sussex University Hospitals NHS Trust, Brighton), Mark De Belder (The 
James Cook University Hospital, Middlesborough), Ever Grech (South Yorkshire Cardiothoracic Center 
- Northern General Hospital,Sheffield), Philip Strike (Queen Alexandra Hospital, Portsmouth Hospitals 
NHS Trust, Portsmouth), Piers Clifford (Harefield Hospital, Uxbridge), Simon James Walsh (Belfast 
City Hospital, Belfast) 
 
Germany : Gert Richardt (Herzzentrum Segeberger Kliniken, Bad Segeberg, Germany), Philip Lurz 
(Universität Leipzig – Herzzentrum, Leipzig), Florian Krackhardt  (Charité Campus Virchow Klinikum, 
Berlin), Franz-Josef Neumann (Zentrum Bad Krozingen, Freiburg), Werner Jung (Schwarzwald-Baar 
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Klinikum, Villingen-Schwenningen), Christoph Naber (Klinik für Kardiologie und Angiologie 
Elisabeth-Krankenhaus, Essen) 
 
Spain:  Andres Iñiguez (Complejo Hospital Meixoeiro, Vigo, Spain), Mariano Valdes-Chavarri 
(Arrixaca University Hospital, Murcia, Spain), Agustin Albarran (Hospital 12 de Octubre, Madrid), 
Raul Moreno (University Hospital La Paz, Madrid) 
 
Italy: Roberto Violini (San Camillo Forlanini, Roma), Corrado Tamburino (University of Catania - 
Ferrarotto Hospital, Catania), Antonio Bartorelli (University of Milan - Centro Cardiologico Monzino, 
Milano), Maurizio Tespili (Ospedale Bolognini, Seriate – Bergamo), Silvio Klugmann (Ospedale 
Niguarda Ca’ Granda, Milano), Antonio Colombo (San Raffaele Hospital, Milano)   
 
Switzerland: Franz Eberli (Triemli Hospital, Zürich), Oliver Gaemperli (University Hospital Zürich, 
Zürich), Eric Eeckhout (Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne), Tiziano 
Moccetti (Cardiocentro Ticino, Lugano), Philip Urban (La Tour Hospital, Geneva) 
 
Singapore: Paul Ong (Tan Tock Seng Hospital), Lim Soo Teik (National Heart Centre Singapore) Chan 
Koo Hui (National University Health System) 
 
Denmark: Evald H Christiansen (Aarhus University Hospital, Skejby, Aarhus), Thomas Engström 
(Rigshospitalet, Copenhagen University Hospital, Copenhagen), 
 
Hong Kong: Stephen Lee (Queen Mary Hospital, Hong Kong) 
Malaysia: Robayaah Zambahari (Institute Jantung Negara, Kuala Lumpur) 
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Australia: Ian Meredith (Monash Heart, Monash Medical Centre, Clayton, Victoria), Darren Walters 
(Prince Charles Hospital, Queensland) 
 
Thailand: Damras Tresukosol (Siriraj Hospital, Bangkok) 
 
Belgium: Stefan Verheye (ZNA Middleheim, Antwerpen), Christophe Dubois (UZ Leuven, Department 
of cardiovascular medicine acute and interventional cardiology, Leuven) 
 
Israel: Ran Kornowski (Rabin Medical Center, Beilinson & Hasharon Hospitals), Petah Tikva), Haim 
Danenberg (Hadassah Hebrew University Medical Center, Jerusalem), Shmuel Banai (Tel Aviv Medical 
Center, Tel Aviv) 
 
Latvia: Andrejs Erglis (Latvian Center of Cardiology Pauls Stradins Clinical University Hospital, Riga) 
 
Norway:  Rune Wiseth (Trondheim University Hospital, Trondheim) 
 
The Netherlands: Marcel Gosselink (Isala Klinieken Zwolle, Zwolle) 
 
Canada: Luc Bilodeau and Sonny Dandona (Royal Victoria Hospital Centre (CUSM), Montreal) 
 
Ireland: David Foley (Beaumont Hospital, Dublin) 
 
Austria: Irene Lang (Medical University of Vienna, Department of Cardiology, Vienna) 
  
 
Study Coordinator Steering Committee: 
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Lars Jørgensen (Aarhus University Hospital, Skejby, Aarhus, Denmark) Karen Wilson (St Thomas’ 
Hospital, London, UK), Laure Morsiani (ICPS, Massy, France), Françoise Hupel (Clinique Saint 
Hilaire, Rouen, France), Ute Windhovel (Cardiovascular European Research Center). 
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B: Inclusion and exclusion criteria 
 
Inclusion criteria: 
 
Any indication for PCI in patients presenting as stable angina, silent ischemia, ACS (STEMI and non-
STEMI), with native or non-native, de novo or in-stent restenosis target lesions, deemed at high risk for 
bleeding and candidates for 1 month DAPT, satisfying at least one on the following criteria:   
1. Adjunctive oral anticoagulation treatment planned to continue after PCI  
2. Age ≥ 75 years old  
3. Baseline Hemoglobin <11 g/dl (or anemia requiring transfusion during the 4 weeks prior to 
randomization)  
4. Any prior intra-cerebral bleed  
5. Any stroke in the last 12 months  
6. Hospital admission for bleeding during the prior 12 months  
7. Non skin cancer diagnosed or treated < 3 years  
8. Planned daily NSAID (other than aspirin) or steroids for >30 days after PCI  
9. Planned surgery that would require interruption of DAPT (within next 12 months)  
10. Renal failure defined as calculated creatinine clearance <40 ml/min  
11. Thrombocytopenia (PLT <100,000/mm3)  
12. Severe chronic liver disease defined as patients who have developed any of the following: variceal 
hemorrhage, ascites, hepatic encephalopathy or jaundice  
13. Expected non-compliance to prolonged DAPT for other medical reasons  
Exclusion criteria: 
1. Pregnant and breastfeeding women  
2. Patients expected not to comply with 1 month DAPT  
3. Patients requiring a planned staged PCI procedure more than one week after the index procedure  
4. Procedure planned to require non-study stents, or stand-alone POBA or stand-alone atherectomy  
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5. Active bleeding at the time of inclusion  
6. Reference vessel diameter <2.25 - >4.0mm  
7. Cardiogenic shock  
8. Compliance with long-term single anti-platelet therapy unlikely  
9. Known hypersensitivity or contraindication to aspirin, clopidogrel (or prasugrel, or ticagrelor if 
applicable), stainless steel, zinc, umirolimus (also known as biolimus A9) or a sensitivity to contrast 
media, which cannot be adequately pre-medicated  
10. PCI during the previous 12 months for a lesion other than the target lesion of the index procedure  
11. Participation in another clinical trial (up to 12 months after index procedure)  
12. Patients with a life expectancy of < 1 year  
13. Patients under judicial protection, tutorship or curatorship (for France only)  
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C: Study devices 
The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three 
components including 1) a 316 L stainless steel bare metal stent platform which has been modified with 
a proprietary surface treatment resulting in a selectively micro-structured, abluminal surface. The 
selectively micro-structured surface allows 2) the drug, umirolimus [also known as biolimus A9], to 
adhere to the abluminal surface of the stent without the use of a polymer or binder. The drug-coated 
stent is crimped onto 3) a delivery system which includes a high pressure, semi-compliant balloon 
incorporated onto the distal tip of a rapid exchange delivery catheter system. The delivery system has 
two radiopaque markers inside the balloon, which fluoroscopically mark the ends of the stent to 
facilitate proper stent placement.  
Umirolimus [biolimus A9] is the therapeutic agent used in the BioFreedom DCS. It is a proprietary 
semi-synthetic sirolimus derivative, highly lipophilic, rapidly absorbed in tissues, and able to reversibly 
inhibit growth factor-stimulated cell proliferation. Current data suggest that umirolimus, on a molecular 
level, forms a complex with the cytoplasmic proteins that inhibit the cell cycle between the G0 and G1 
phase. The result is an interruption of the cascade governing cell metabolism, growth, and proliferation. 
For this trial, the BioFreedom DCS was available in six stent diameters (2.25 – 4.0 mm), seven lengths 
(8-28mm) and one drug dosage (15.6 µg/mm).  
The control Gazelle bare metal stent (BMS) consists of a very similar stainless steel platform (the 
connecting struts are straight instead of curved, a difference not visible to the naked eye), but without 
the micro-structured abluminal surface or the drug, crimped onto the same balloon delivery system. 
Both devices were packaged in a numbered but identical non-branded generic fashion, thus allowing for 
a full double-blind design. Information regarding both the BioFreedom DCS and Gazelle BMS were 
provided in the Instructions for Use for the Leaders Free study.   
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D: Endpoint definitions 
 
The primary safety endpoint (non-inferiority and superiority hypotheses) was the cumulative incidence 
of a composite of cardiac death, myocardial infarction (MI), and definite or probable stent thrombosis at 
1 year.  
The primary efficacy endpoint (superiority hypothesis) was the incidence of clinically driven TLR at 1 
year. 
Cardiac death was defined as death due to any of the following:  
Acute myocardial infarction.  
Cardiac perforation/pericardial tamponade.  
Arrhythmia or conduction abnormality.  
Stroke within 30 days of the procedure or stroke suspected of being related to the procedure.  
Death due to complication of the procedure, including bleeding, vascular repair, transfusion 
reaction, or bypass surgery.  
Any death in which a cardiac cause cannot be excluded.  
Myocardial infarction was defined according to the third universal definition: 
The term acute myocardial infarction (MI) should be used when there is evidence of myocardial 
necrosis in a clinical setting consistent with acute myocardial ischemia. Under these conditions any one 
of the following criteria meets the diagnosis for MI:  
1) Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at 
least one value above the 99th percentile upper reference limit (URL) and with at least one of the 
following:  
o Symptoms of ischemia.  
o New or presumed new significant ST-segment–T wave (ST–T) changes or new left 
bundle branch block (LBBB).  
o Development of pathological Q waves in the ECG.  
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o Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality.  
o Identification of an intracoronary thrombus by angiography or autopsy. 
2) Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG 
changes or new LBBB, but death occurred before cardiac biomarkers were obtained, or before cardiac 
biomarker values would be increased.  
3) Percutaneous coronary intervention (PCI) related MI is arbitrarily defined by elevation of cTn values 
(>5 x 99th percentile URL) in patients with normal baseline values (≤99th percentile URL) or a rise of 
cTn values >20% if the baseline values are elevated and are stable or falling. In addition, either (i) 
symptoms suggestive of myocardial ischemia or (ii) new ischemic ECG changes or (iii) angiographic 
findings consistent with a procedural complication or (iv) imaging demonstration of new loss of viable 
myocardium or new regional wall motion abnormality are required.  
4) Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting 
of myocardial ischemia and with a rise and/or fall of cardiac biomarker values with at least one value 
above the 99th percentile URL.  
5) Coronary artery bypass grafting (CABG) related MI is arbitrarily defined by elevation of cardiac 
biomarker values (>10 x 99th percentile URL) in patients with normal baseline cTn values (≤99th 
percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic 
documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of 
viable myocardium or new regional wall motion abnormality. 
 
Types of myocardial infarction 
Type 1: Spontaneous myocardial infarction  
Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, 
erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary 
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arteries leading to decreased myocardial blood flow or distal platelet emboli with ensuing 
myocyte necrosis. The patient may have underlying severe CAD but on occasion non-obstructive 
or no CAD. 
 
Type 2: Secondary myocardial infarction  
In instances of myocardial injury with necrosis where a condition other than CAD contributes to 
an imbalance between myocardial oxygen supply and/or demand, e.g. coronary endothelial 
dysfunction, coronary artery spasm, coronary embolism, tachy-/brady-arrhythmias, anemia, 
respiratory failure, hypotension, and hypertension with or without LVH.  
 
Type 3: Myocardial infarction related to sudden cardiac death  
Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic 
ECG changes or new LBBB, but death occurring before blood samples could be obtained, before 
cardiac biomarker could rise, or in rare cases cardiac biomarkers were not collected.  
 
Type 4a: Myocardial infarction related to percutaneous coronary intervention (PCI).  
Myocardial infarction associated with PCI is arbitrarily defined by elevation of cTn values >5 x 
99th percentile URL in patients with normal baseline values (≤99th percentile URL) or a rise of 
cTn values >20% if the baseline values are elevated and are stable or falling. In addition, either 
(i) symptoms suggestive of myocardial ischemia, or (ii) new ischemic ECG changes or new 
LBBB, or (iii) angiographic loss of patency of a major coronary artery or a side branch or 
persistent slow or no-flow or embolization, or (iv) imaging demonstration of new loss of viable 
myocardium or new regional wall motion abnormality are required.  
 
Type 4b: Myocardial infarction related to stent thrombosis  
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Myocardial infarction associated with stent thrombosis is detected by coronary angiography or 
autopsy in the setting of myocardial ischemia and with a rise and/or fall of cardiac biomarkers 
values with at least one value above the 99th percentile URL.  
 
Type 4c : Myocardial infarction related to in-stent restenosis 
 
Type 5: Myocardial infarction related to coronary artery bypass graft surgery (CABG)  
Myocardial infarction associated with CABG is arbitrarily defined by elevation of cardiac 
biomarker values >10 x 99th percentile URL in patients with normal baseline cTn values (≤99th 
percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) 
angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging 
evidence of new loss of viable myocardium or new regional wall motion abnormality 
 
Stent thrombosis was defined according to the Academic Research Consortium (ARC). 
 
Acute stent thrombosis 0 – 24 hours post stent implantation  
Sub-acute stent thrombosis  > 24 hours – 30 days post stent 
implantation  
Late stent thrombosis > 30 days – 1 year post stent 
implantation  
Very late stent thrombosis  > 1 year post stent implantation  
 
Definite stent thrombosis is considered to have occurred by either angiographic or pathologic 
confirmation. 
Probable stent thrombosis is considered to have occurred after intracoronary stenting in the 
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following cases:  
1) Any unexplained death within the first 30 days.  
2) Irrespective of the time after the index procedure any MI, which is related to 
documented acute ischemia in the territory of the implanted stent without angiographic 
confirmation of stent thrombosis and in the absence of any other obvious cause 
Possible stent thrombosis is considered to have occurred with any unexplained death from 30 
days following intracoronary stenting until end of trial follow-up. 
 
Bleeding was defined according to the Bleeding Academic Research Consortium (BARC) 
Type 0 : no bleeding  
 
Type 1 : bleeding that is not actionable and does not cause the patient to seek unscheduled 
performance of studies, hospitalization, or treatment by a healthcare professional ; may include 
episodes leading to self-discontinuation of medical therapy by the patient without consulting a 
healthcare professional  
 
Type 2 : any overt, actionable sign of hemorrhage (eg. More bleeding than would be expected 
for a clinical circumstance, including bleeding found by imaging alone) that does not fit the 
criteria for type 3, 4 or 5 but does meet at least one of the following criteria : (1) requiring 
nonsurgical, medical intervention by a healthcare professional, (2) leading to hospitalization or 
increased level of care, or (3) prompting evaluation.  
 
Type 3 :  
 Type 3a :  
 - overt bleeding plus hemoglobin drop of 3 to <5 g/dL* (provided hemoglobin  drop is 
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related to bleed  
 - any transfusion with overt bleeding  
Type 3b :  
- overt bleeding plus hemoglobin drop ≥ 5 g/dl (provided hemoglobin drop is related to 
bleed)  
- cardiac tamponade  
- bleeding requiring surgical intervention for control (excluding 
dental/nasal/skin/hemorrhoid)  
- bleeding requiring intravenous vasoactive agents  
Type 3c :  
- intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, 
does include intraspinal)  
- subcategories confirmed by autopsy or imaging or lumbar puncture  
- intraocular bleed compromising vision  
 
Type 4: CABG-related bleeding  
- perioperative intracranial bleeding within 48 h  
- reoperation after closure of sternotomy for the purpose of controlling bleeding  
- transfusion of ≥5 U whole blood or packed red blood cells within a 48-h period†  
- chest tube output ≥2L within a 24-h period  
 
Type 5: fatal bleeding  
Type 5a:  probable fatal bleeding; no autopsy or imaging confirmation but clinically 
suspicious  
Type 5b: definite fatal bleeding; overt bleeding or autopsy or imaging confirmation 
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Clinically-driven target lesion revascularization (TLR) was defined as PCI or surgery for either an 
operator-defined restenosis in the treated lesion together with angina symptom and/or documented 
ischemia or for a > 70% core-laboratory defined restenosis when neither symptoms or ischemia were 
present.  
 
Urgent TLR was defined as TLR done within 48 hours after hospital admission for symptomatic in-stent 
restenosis or stent thrombosis associated with new resting ECG changes and/or a rise of biomarkers 
(CK/MB or troponin). 
 
Device success was defined as the successful delivery and deployment of a study stent to the target 
lesion with an estimated <20% residual stenosis and either a TIMI flow 3 or a consistent TIMI flow 2 
before and after the procedure using study stents only.  
 
Lesion success was defined as the successful delivery and deployment of a study stent to the target 
lesion with an estimated <20% residual stenosis and either a TIMI flow 3 or a consistent TIMI flow 2 
before and after the procedure using any percutaneous method and/or non-study stents.  
 
Procedure success was the successful treatment of all target lesions without the occurrence of death, MI, 
or target vessel repeat revascularization during the hospital stay.  
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E: Methods for time-updated Cox proportional hazards models  
To model the effect of major bleeding or thrombotic events on subsequent death, we used Cox 
proportional hazards models with a time updated covariate, a well-established statistical methodology 
(see for example “Andersen, Encylopedia of Biostatistics,2005, Chapter: Time-Dependent covariates”). 
This is achieved by splitting records for an individual into relevant segments of follow up and then 
running a proportional hazards model on the modified data. For example, suppose who has a bleeding 
event after 69 days and subsequently dies after 300 days. Their original record is: 
 
Subject ID Death Start of 
Follow up 
End of 
follow up 
Time to 
major 
bleeding 
1 1 0 300 69 
 
To fit a model with a time-varying covariate the data is modified to: 
Subject 
ID 
Death Start of 
Follow 
up 
End of 
follow 
up 
Time to 
major 
bleeding 
After 
major 
bleeding 
1 0 0 69 69 0 
1 1 69 300 69 1 
 
The covariate in the “after switch” column can now be used to compare the rate of death before 
and after major bleeding events. Splitting follow up into time periods (0-7, 8-30, >30 days) after 
the event is a natural extension of this methodology. From a technical standpoint the new hazard 
function becomes: 
 
ℎ = exp	∝  +  + ) 
 
where ∝  is the baseline hazard function, represents a “normal” (ie one that does not 
change over time), and   represents a covariate that is allowed to vary over time.  then 
represents the log hazard ratio per unit change in the time-dependent covariate.  
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F: Supplementary Tables and Figures 
 
 
Table S1. Covariates assessed for inclusion in prediction models for major bleedings and 
thrombotic events 
 
Patient characteristics Procedural characteristics 
Age Type of trial stent 
Gender SVG target lesion (1 or more) 
BMI Bifurcation target lesion (1 or more) 
Hypertension Total stent length 
Hypotension (<100 mmHg at baseline)  Maximum stent diameter  
Measured systolic BP at baseline 
(continuous) Overlapping stents implanted 
Active smoker Number of stents implanted 
Congestive heart failure Multivessel procedure 
Peripheral arterial disease Residual stenosis reported > 50% or final TIMI flow < 3 
Prior CABG or PCI GP IIb-IIIa blockers used during procedure 
Prior MI 
 
Prior stroke 
  
Planned use of OAC post-PCI 
  
Non-skin cancer < 3 years 
  
Creatinine clearance < 40 ml/min 
  
Plasma creatinine  
  
Hemoglobin < 11 g/dl or recent TF or 
admission for bleeding < 1 year   
Hemoglobin    
Surgery planned < 1 year 
  
Diabetes 
  
ACS presentation (NSTEMI or STEMI) 
  
Multivessel disease 
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Figure S2: Study group assignment and follow-up 
 
 
 
PCI denotes percutaneous coronary intervention, BMS, Bare-metal stent, DCS, Drug-coated  
stent. 
 
Note: the 24 month follow-up contact was scheduled to take place after 24 months + 60 days. Because a 
significant proportion of patients were contacted during the earlier part of that time-window, the number 
of patients at risk at 730 days is reduced in Figure 1 A and B. 
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Table S3 Baseline Patient Characteristics and Inclusion Criteria 
 
  
DCS, N (%) 
(n=1,221) 
BMS, N (%)
(n=1,211) 
Mean age 75.7±9.4 75.7±9.3 
Female gender 364 (29.8) 374 (30.9) 
Mean BMI 27.5±4.8 27.2±4.6 
Diabetes 414 (34.0) 391 (32.3) 
Hypertension 952 (78.1) 961 (79.6) 
Hypercholesterolemia 742 (62.0) 746 (62.7) 
STEMI 57 (4.7) 48 (4.0) 
NSTEMI 273 (22.4) 281 (23.2) 
Unstable angina 177 (14.5) 193 (15.9) 
Stable CAD 714 (58.5) 689 (56.9) 
Multi vessel disease 755 (62.9) 738 (61.6) 
Prior myocardial infarction 237 (19.6) 258 (21.4) 
Previous PCI 270 (22.2) 265 (21.9) 
Previous CABG 115 (9.4) 122 (10.1) 
Congestive heart failure 175 (14.4) 150 (12.4) 
Atrial Fibrillation 424 (34.9) 418 (34.6) 
Previous stroke 132 (10.9%) 110 (9.1%) 
Peripheral vascular disease 190 (15.7) 190 (15.8) 
Chronic obstructive lung disease 131 (10.9) 141 (11.7) 
CRUSADE score 34.1 + 0.4 34.6 + 0.4 
 
  
Inclusion criteria+ 
Age >=75 788 (64.5) 776 (64.1) 
Planned continued OAC 448 (36.7) 431 (35.6) 
Hemoglobin < 11g/l or transfusion <=30 
days 185 (15.2) 194 (16.0) 
Platelets < 100,000/m3 20 (1.6) 18 (1.5) 
Admission for bleeding in last year 46 (3.8) 33 (2.7) 
Stroke in last year 15 (1.2) 24 (2.0) 
Previous intra-cerebral hemorrhage 14 (1.1) 19 (1.6) 
Severe Chronic Liver Disease 11 (0.9) 10 (0.8) 
Creatinine clearance <40 ml/min 219 (17.9) 245 (20.2) 
Cancer in last 3 years* 119 (9.7) 120 (9.9) 
Planned major surgery in following year 187 (15.3) 211 (17.4) 
Steroids / NSAID planned >30 days post 
PCI 38 (3.1) 34 (2.8) 
Expected noncompliance for >30 days 
DAPT 41 (3.4) 47 (3.9) 
None of the baseline characteristics differ at p<0.05 
+ not mutually exclusive 
* excludes skin cancer 
^Mean ± standard deviation 
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BMS: bare metal stent; BMI: body mass index; CABG: coronary artery bypass grafting; CAD: coronary 
artery disease; DAPT: dual antiplatelet therapy; DCS: drug coated stent; NSAID: non-steroid anti-
inflammatory drug; NSTEMI: non-ST elevation myocardial infarction; OAC: oral anticoagulation; PCI: 
percutaneous coronary intervention; STEMI: ST elevation myocardial infarction 
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Table S4: antithrombotic medication during follow-up 
Medication DCS n (%) BMS n (%) p-value 
At discharge    
DAPT at discharge 1176 (96.6) 
((96.6) (96.5)
1172 (96.9) 
(96.9) 
0.52 
Aspirin + Clopidogrel 1099(90.0) 
(90.2) 
1101(90.9) 
(91.1) 
0.44 
Aspirin + Prasugrel 13 (1.1) 16 (1.3) 0.56 
Aspirin + Ticagrelor 63 (5.2) 54 (4.5) 0.42 
Aspirin + Ticlopidine 1 (0.1) 1 (0.1) 1.00 
OAC at discharge 443 (36.3) 418 (34.6) 0.36 
AVK 394 (32.3) 382 (31.6) 0.70 
Other OAC 49 (4.0) 36 (3.0) 0.18 
Triple therapy (OAC + DAPT) 408 (33.5) 387 (32.0) 0.44 
AVK + Clopidogrel alone 32 (2.6) 30 (2.5) 0.82 
 
   
1 month 
     DAPT at start of 1 month follow up window* 1146 (95.3) 1135 (95.0) 0.85 
     DAPT at end of 1 month follow up window* 110 (9.2) 116 (9.7) 0.65 
No APT  15 (1.3)  12 (1.0)  0.58 
     OAC 410 (34.6) 387  (33.0) 0.43  
 
   
12 month    
DAPT 85 (7.7) 106 (9.7)  0.10 
SAPT    928 (83.8) 903 (82.9)  0.54 
Aspirin 802 (85.7) 778 (85.8)  0.95 
       Clopidogrel 124 (13.7) 127 (13.6)  0.95 
       Ticagrelor 4 (0.4) 3 (0.3) 0.73 
       Prasugrel 3 (0.3) 2 (0.2) 0.68 
       Ticlopidine 0 (0.0) 0 (0.0) NA 
No APT 95 (8.6) 80 (7.3) 0.35 
     OAC 416 (37.5) 405 (37.2) 0.66 
 
   
24 month    
DAPT 55 (5.3) 78 (7.6) 0.03 
SAPT    816 (78.8) 784 (76.8) 0.26 
Aspirin 731 (89.5) 692 (88.3) 0.40 
       Clopidogrel 82 (10.5) 87 (11.1) 0.49 
       Ticagrelor 0 (0) 4 (0.5) 0.06 
       Prasugrel 3 (0.4) 1 (0.1) 0.67 
       Ticlopidine 0 (0.0) 0 (0.0) NA 
No APT 164 (15.8)  159 (15.6) 0.87 
OAC 390 (37.7) 388 (38.0) 0.88 
APT: antiplatelet therapy; AVK: anti-vitamin K; DAPT: dual antiplatelet therapy; OAC: oral 
anticoagulant; SAPT: single antiplatelet therapy 
• One month follow up window from 23 to 37 days  
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Supplementary Figure S5: Subgroup analyses for the primary safety and primary efficacy endpoints at 
2-year follow-up 
 
 
 
 
  
Scores on the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse 
Outcomes with Early Implementation of the American College of Cardiology/American Heart 
Association Guidelines) bleeding risk scale (range from 1 to 100, with higher scores indicating a higher 
risk of major bleeding). The median score of 35 in our trial was chosen as the cutoff value. Cancer 
excluded skin cancer. ACS denotes acute coronary syndrome, and OAC oral anticoagulation. 
Age >80
No
Yes
Male
No
Yes
ACS at admission
No
Yes
Diabetes
No
Yes
Renal failure at admission
No
Yes
Planned OAC at randomization
No
Yes
Crusade score > median (35)
No
Yes
Anemia, transfusion or bleeding leading to hospitalization
No
Yes
Planned major surgery in following year
No
Yes
Cancer in last 3 years*
No
Yes
Multi-vessel disease at admission
No
Yes
Total stent length > 30 mm
No
Yes
Minimal stent diameter < 3 mm
No
Yes
Category
1602
830
738
1694
1773
659
1622
805
1754
466
1553
879
1061
962
2007
425
2000
406
2193
239
906
1493
1409
999
1195
1213
N
41 (5.5)
36 (9.4)
21 (6.3)
56 (7.0)
62 (7.5)
15 (5.0)
52 (7.1)
25 (6.4)
56 (6.8)
19 (9.5)
47 (6.4)
30 (7.5)
31 (6.4)
40 (9.2)
58 (6.2)
19 (9.8)
66 (7.1)
9 (4.8)
73 (7.1)
4 (3.5)
15 (3.5)
61 (8.9)
27 (4.2)
50 (10.3)
31 (5.5)
46 (8.2)
Events (%)
DCS:
90 (11.9)
46 (12.1)
42 (12.1)
94 (12.0)
105 (12.6)
31 (10.4)
92 (11.9)
44 (12.2)
100 (12.1)
22 (10.4)
92 (12.4)
44 (11.2)
65 (12.6)
45 (10.2)
114 (12.0)
22 (12.3)
110 (11.9)
25 (12.5)
123 (12.0)
13 (11.9)
37 (8.6)
97 (14.1)
64 (9.4)
71 (16.1)
48 (8.5)
87 (15.5)
Events (%)
BMS:
0.07
0.67
0.49
0.79
0.14
0.43
0.04
0.18
0.45
0.30
0.27
0.27
0.39
interaction
P-value for
1.125 .25 .5 2 4
Hazard ratio (95% CI)
Efficacy endpoint
(clinically driven TLR)
Age >80
No
Yes
Male
No
Yes
ACS at admission
No
Yes
Diabetes
No
Yes
Renal failure at admission
No
Yes
Planned OAC at randomization
No
Yes
Crusade score > median (35)
No
Yes
Anemia, transfusion or bleeding leading to hospitalization
No
Yes
Planned major surgery in following year
No
Yes
Cancer in last 3 years*
No
Yes
Multi-vessel disease at admission
No
Yes
Total stent length > 30 mm
No
Yes
Minimal stent diameter < 3 mm
No
Yes
Category
1602
830
738
1694
1773
659
1622
805
1754
466
1553
879
1061
962
2007
425
2000
406
2193
239
906
1493
1409
999
1195
1213
N
80 (10.3)
67 (16.9)
43 (12.4)
104 (12.6)
106 (12.4)
41 (13.0)
87 (11.4)
60 (14.9)
97 (11.3)
39 (18.8)
85 (11.5)
62 (14.4)
47 (9.4)
81 (17.9)
112 (11.6)
35 (17.4)
124 (12.7)
20 (10.9)
135 (12.7)
12 (10.6)
32 (7.5)
111 (15.4)
72 (11.0)
73 (14.4)
64 (11.2)
81 (13.8)
Events (%)
DCS:
106 (13.5)
74 (18.7)
62 (17.0)
118 (14.5)
113 (13.0)
67 (21.5)
106 (13.2)
74 (19.7)
106 (12.6)
60 (25.5)
117 (15.4)
63 (15.0)
58 (11.0)
99 (21.2)
129 (13.1)
51 (26.3)
147 (15.3)
29 (13.9)
163 (15.3)
17 (15.4)
46 (10.3)
131 (18.2)
87 (12.4)
89 (19.1)
71 (12.3)
105 (17.8)
Events (%)
BMS:
0.52
0.42
0.05
0.73
0.34
0.26
1.00
0.22
0.80
0.81
0.63
0.35
0.37
interaction
P-value for
1.125 .25 .5 2 4
Hazard ratio (95% CI)
Composite safety endpoint
(cardiac death, MI, ST)
